Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.

Vanderbilt's James Crowe Jr., MD, was among those to receive 2023 Advocacy Awards from Research!America at the biomedical research advocacy organization’s annual awards program in Washington, D.C.

Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself.

Vanderbilt University and Vanderbilt University Medical Center climbed seven spots in a survey by the National Science Foundation that measures annual research and development expenditures.

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.